Targeting ALS10: A Potential Drug Target and Biomarker for Amyotrophic Lateral Sclerosis

Target Name: TARDBP

NCBI ID: G23435

Targeting ALS10: A Potential Drug Target and Biomarker for Amyotrophic Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease characterized by the progressive loss of motor neurons. The most common form of ALS is ALS-related Degenerative Brain Disease (ADBD), which is caused by the progressive loss of motor neurons in the brainstem and spinal cord. The progressive loss of motor neurons results in progressive muscle weakness and wasting, which can lead to a range of challenging and life-threatening symptoms, including difficulty swallowing, muscle weakness, and loss of independence.

Targeting ALS10: The Potential Drug Target

The search for new treatments and biomarkers for ALS has led to the identification of potential drug targets. One such potential drug target is ALS10, a protein that is expressed in the brain and has been shown to be involved in the development and progression of ALS.

ALS10 is a member of the TARDBP family, which includes other proteins that have been implicated in the development and progression of ALS, including TARDBP1, TARDBP2, and TARDBP3. These proteins are part of a superfamily of transmembrane proteins that are characterized by their ability to interact with a variety of ligands, including neurotransmitters and other proteins.

The Identification of ALS10 as a Potential Drug Target

The identification of ALS10 as a potential drug target comes from a combination of experimental data and computational analysis. First, studies have shown that ALS10 is involved in the development and progression of ALS, and that its levels are reduced in individuals with ALS. Second, computational analysis has identified a variety of potential drug targets for ALS10, including interacting proteins and chemical modifications on the protein.

One of the most promising potential drug targets for ALS10 is the neurotransmitter acetylcholine, which is known to play a role in the development and progression of ALS. Studies have shown that ALS10 is involved in the regulation of acetylcholine levels in the brain, and that its levels are reduced in individuals with ALS. Additionally, computational analysis has identified potential binding sites on the ALS10 protein for the neurotransmitter acetylcholine, suggesting that it may be a target for ALS10 inhibitors.

Another potential drug target for ALS10 is the protein tyrosine phosphatase (PTP), which is a enzyme that is involved in the regulation of many signaling pathways in the brain. Studies have shown that ALS10 is involved in the regulation of PTP levels in the brain, and that its levels are reduced in individuals with ALS. Additionally, computational analysis has identified potential binding sites on the ALS10 protein for PTP inhibitors, suggesting that it may be a target for ALS10 inhibitors.

The Identification of ALS10 as a Potential Biomarker

The identification of ALS10 as a potential drug target also suggests that it may be a useful biomarker for the diagnosis and progression of ALS. ALS is a progressive neurodegenerative disease, and the progressive loss of motor neurons that occurs in ALS can be used as a biomarker for the disease.

Studies have shown that ALS10 is expressed in the brain and that its levels are reduced in individuals with ALS. Additionally, studies have shown that ALS10 is involved in the regulation of many signaling pathways in the brain, including those that are involved in the development and progression of ALS.

The potential use of ALS10 as a biomarker for ALS comes from a combination of experimental data and computational analysis. First, studies have shown that ALS10 is expressed in the brain and that its levels are reduced in individuals with ALS

Protein Name: TAR DNA Binding Protein

Functions: RNA-binding protein that is involved in various steps of RNA biogenesis and processing (PubMed:23519609). Preferentially binds, via its two RNA recognition motifs RRM1 and RRM2, to GU-repeats on RNA molecules predominantly localized within long introns and in the 3'UTR of mRNAs (PubMed:23519609, PubMed:24240615, PubMed:24464995). In turn, regulates the splicing of many non-coding and protein-coding RNAs including proteins involved in neuronal survival, as well as mRNAs that encode proteins relevant for neurodegenerative diseases (PubMed:21358640, PubMed:29438978). Plays a role in maintaining mitochondrial homeostasis by regulating the processing of mitochondrial transcripts (PubMed:28794432). Regulates also mRNA stability by recruiting CNOT7/CAF1 deadenylase on mRNA 3'UTR leading to poly(A) tail deadenylation and thus shortening (PubMed:30520513). In response to oxidative insult, associates with stalled ribosomes localized to stress granules (SGs) and contributes to cell survival (PubMed:23398327, PubMed:19765185). Participates also in the normal skeletal muscle formation and regeneration, forming cytoplasmic myo-granules and binding mRNAs that encode sarcomeric proteins (PubMed:30464263). Plays a role in the maintenance of the circadian clock periodicity via stabilization of the CRY1 and CRY2 proteins in a FBXL3-dependent manner (PubMed:27123980). Negatively regulates the expression of CDK6 (PubMed:19760257). Regulates the expression of HDAC6, ATG7 and VCP in a PPIA/CYPA-dependent manner (PubMed:25678563)

More Common Targets